Insight Brief

3 Tools You Should Be Using Now to Improve Oncology Care through Minimal Residual Disease Testing

Minimal Residual Disease: Finding the Right Test for the New Definition of Remission

Measurement of residual disease (MRD) is one of the most reliable predictors of treatment outcomes for patients with leukemia, lymphoma, and myeloma. Because of this, global central laboratories like Q2 Solutions will have an increasingly important role to play in MRD testing.

In this complimentary insight brief you'll learn how 3 key technologies – Next Generation Sequencing, Flow Cytometry, and Polymerase Chain Reaction – help pharmaceutical and biotechnology companies predict better treatment outcomes through MRD testing.

Contact us today to discover how we can use our deep scientific expertise and global laboratory footprint to improve patient care in your MRD testing programs.

Download

More Resources

2 Essential Approaches You Should be Using Now for Minimal Residual Disease Detection in Oncology
How Flow Cytometry Advances Immuno-oncology Clinical Trial Studies
How Immune Repertoire Sequencing Advances Immuno-oncology Biomarker Development Programs
View All